Search

Learn how MSK cares for transgender cancer patients, treating them with respect and medical expertise. Staff are specially trained to understand their needs.

… Friday, May 31, 2024 As Susan Everson lay in bed recovering from colorectal cancer surgery at Memorial Sloan Kettering Cancer Center (MSK), a nurse walked into her room with bag of cosmetics and a big dose of compassion. Using her skills as a professionally trained makeup artist, she’d come to help Susan

A study led by postdoctoral researcher Yanan Ma from the lab of cell biologist Philipp Niethammer shows why diversity also matters in model animal research.

… Tuesday, January 10, 2023 In science, how you ask a question is often as important as what you ask. Philipp Niethammer Philipp Niethammer, PhD The lab of cell biologist Philipp Niethammer, PhD , of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK), studies fast-acting mechanisms

Investigators are looking at how and why the breast cancer drug trastuzumab sometimes causes long-lasting and potentially serious cardiac side effects.

… Thursday, October 19, 2017 Summary The breast cancer drug trastuzumab, which targets a protein called HER2, can cause long-lasting and potentially serious cardiac side effects. Researchers are using stem cells to study why this happens and to look for ways to prevent it. For people with breast cancer

Learn about how to cope with grief during the holidays from MSK Experts.

… Tuesday, December 13, 2016 Summary MSK experts provide advice on how to cope with grief during the holiday season. It’s important to reevaluate rituals, seek support, and remain aware of your own mental health. Highlights Seek support: Surround yourself with others who’ve experienced what you have. Accept

Expand your knowledge of melanoma with these surprising facts.

… Tuesday, May 11, 2021 Summary Does melanoma always develop from a mole? Can melanoma be pink? Read on to expand your knowledge of the disease. Compared to other cancers, melanoma  may seem fairly straightforward. But there’s more to this disease than meets the eye. Dermatologist Ashfaq Marghoob of the

Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared with BR alone, according to new findings presented by a Memorial Sloan Kettering (MSK) investigator on behalf of his international co-investigators. Results from the phase III study were presented as part of the press program at this year’s American Society of Hematology annual meeting.

… Sunday, December 6, 2015 Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared

The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.

… Sunday, September 20, 2020 Summary In a study of people with lung cancer whose tumors contained the mutation targeted by sotorasib, 52 of 59 patients experienced disease control, which means that their tumors stopped growing. Update: On January 30, 2021, Memorial Sloan Kettering lung cancer expert Bob

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Larry Norton, MD, has been elected to the American Academy of the Arts & Sciences, and Michel Sadelain, MD, PhD, has been named the recipient of the Outstanding Achievement Award from the American Society of Gene and Cell Therapy.

… Monday, April 26, 2021 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Larry Norton, MD , Senior Vice President, Office of the President; Medical Director, Evelyn H. Lauder Breast Center, has been elected to the American Academy of the Arts & Sciences , and Michel Sadelain, MD,

Investigators have shown how gut microbes promote the formation of a type of immune cell called regulatory T cells.

… Wednesday, April 22, 2020 Summary An MSK team has learned how gut microbes promote the formation of a type of immune cell called regulatory T cells. The research could improve scientists’ understanding of conditions like inflammatory bowel disease. The microscopic organisms that live in our intestines

Learn how a new drug shows great promise for treating pancreatic by targeting the KRAS mutation, which fuels 90% of the disease.

… Tuesday, April 21, 2026 A drug given “breakthrough designation” by the U.S. Food & Drug Administration (FDA) may offer the best new option in many years for people facing pancreatic cancer , one of the most aggressive types of cancer.  Daraxonrasib targets mutations in the RAS gene, which helps control